Related Experiment Video
Updated: Jul 31, 2025
Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
Published on: June 30, 2021
Challenges in scaling up AAV-based gene therapy manufacturing
1Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK.
Accelerating adeno-associated virus (AAV) manufacturing requires streamlining bioprocess development. Quality by Design (QbD) principles, utilizing rapid stress tests and scale-down models, can optimize gene therapy production.
Area of Science:
- Biotechnology and Bioprocessing
- Gene Therapy Manufacturing
- Quality by Design (QbD)
Background:
- The increasing demand for adeno-associated virus (AAV) gene therapies necessitates faster and more efficient manufacturing processes.
- Current AAV bioprocess development is often time-consuming and presents significant challenges.
- The Quality by Design (QbD) framework is crucial for ensuring product quality and safety in biopharmaceutical manufacturing.
Purpose of the Study:
- To review the application of Quality by Design (QbD) principles for accelerating adeno-associated virus (AAV) bioprocess development.
- To explore the potential of rapid stress tests, developability screens, and scale-down technologies in AAV manufacturing.
- To assess the translation of successful antibody manufacturing development tools to AAV gene therapy production.
Main Methods:
- Review of established QbD methodologies, including rapid stress testing and developability screening.
- Analysis of scale-down technologies and their adaptation for adeno-associated virus (AAV) production.
- Evaluation of the transferability of tools and strategies from antibody manufacturing to AAV bioprocesses.
Main Results:
- Rapid stress tests, developability screens, and scale-down technologies show promise for streamlining AAV product and manufacturing bioprocess development within the QbD framework.
- Successful application of these tools in antibody manufacturing provides a foundation for their use in AAV development.
- The effectiveness of these approaches for AAV is contingent upon advancements in analytical methods and adaptive tool utilization.
Conclusions:
- Implementing QbD principles with advanced tools can significantly accelerate adeno-associated virus (AAV) manufacturing scale-up.
- Further development of analytical methods and adaptation of tools are critical for optimizing AAV gene therapy production.
- Successful translation requires a deeper understanding of the critical attributes governing AAV therapeutic efficacy and manufacturability.
More Related Videos
05:51Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production
Published on: May 3, 2024
10:31Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System
Published on: January 13, 2022